Related Experiment Video

Updated: Jun 3, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Myocardial ischemia: a silent epidemic in Type 2 diabetes patients

Claude Le Feuvre1, Sophie Jacqueminet, Olivier Barthelemy

  • 1Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, 47-83 Bd de l'hôpital, 75651 Paris Cedex 13, France. claude.lefeuvre@psl.aphp.fr

Future Cardiology
|April 2, 2011
PubMed

Insights

Screening for silent myocardial ischemia (SMI) in diabetic patients may help detect coronary artery disease (CAD) early. However, benefits are unclear in optimally treated patients, and revascularization is mainly for severe CAD.

Area of Science:

  • Cardiology
  • Diabetology
  • Preventive Medicine

Background:

  • Diabetes mellitus prevalence is rising globally.
  • Coronary artery disease (CAD) is a leading cause of mortality.
  • Silent myocardial ischemia (SMI) is more common in diabetic individuals, potentially leading to early CAD detection and reduced cardiovascular events.

Purpose of the Study:

  • To evaluate the benefit of systematic SMI screening in asymptomatic diabetic patients.
  • To identify subgroups of diabetic patients who may benefit from SMI screening and subsequent revascularization.

Main Methods:

  • Review of current guidelines for SMI screening in diabetic patients.
  • Analysis of the impact of risk factor management on SMI screening benefits.
  • Examination of revascularization benefits in diabetic patients with SMI based on CAD severity.

Main Results:

  • Current guidelines suggest SMI screening for high-risk asymptomatic diabetics, followed by coronary angiography if stress tests are positive.
  • The benefit of systematic SMI screening is not established in diabetic patients with optimally managed risk factors.
  • Revascularization benefits in diabetic patients with SMI appear limited to those with severe CAD.

Conclusions:

  • Further prospective studies are needed to identify diabetic patients who would benefit from SMI screening.
  • Diabetic patients with severe CAD and potential revascularization benefits (e.g., renal failure, LV dysfunction, peripheral/carotid disease) are candidates for further investigation.

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...